Drug Profile
Research programme: Filovirus immunotherapeutics - GeoVax Labs
Alternative Names: GEO EM03; GEO EM05; GOVX E301; GOVX E302; GOVX-E303; Haemorrhagic fever vaccine - GeoVax; Monovalent vaccine - GeoVax; MVA-VLP Ebola vaccine - GeoVax; MVA-VLP tetravalent vaccine - GeoVaxLatest Information Update: 07 Apr 2022
Price :
$50
*
At a glance
- Originator GeoVax Labs
- Class Viral vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Ebola virus infections; Lassa fever
- No development reported Marburg virus disease
Most Recent Events
- 07 Apr 2022 Preclinical development in Lassa fever (Prevention) is still ogoing in USA (IM) (GeoVax Labs pipeline, April 2022)
- 28 Sep 2021 No recent reports of development identified for preclinical development in Ebola-virus-infections(Prevention) in USA (IM)
- 28 Sep 2021 No recent reports of development identified for preclinical development in Lassa-fever(Prevention) in USA (IM)